Epizyme, Inc. (NASDAQ:EPZM)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday.

A number of other research firms also recently issued reports on EPZM. Zacks Investment Research downgraded Epizyme from a “buy” rating to a “hold” rating in a research report on Monday, May 22nd. Wedbush reissued an “outperform” rating and set a $24.00 price target on shares of Epizyme in a research report on Thursday, May 18th. Royal Bank Of Canada reissued an “outperform” rating and set a $20.00 price target (up previously from $19.00) on shares of Epizyme in a research report on Wednesday, May 10th. Cann reissued a “buy” rating and set a $26.00 price target on shares of Epizyme in a research report on Tuesday, April 25th. Finally, ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $23.75.

Shares of Epizyme (NASDAQ EPZM) traded up 0.37% during trading on Monday, reaching $13.55. The company’s stock had a trading volume of 53,626 shares. The stock’s market cap is $790.75 million. The company has a 50-day moving average price of $13.88 and a 200-day moving average price of $14.28. Epizyme has a one year low of $7.02 and a one year high of $18.50.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 58.97% and a negative net margin of 1,376.33%. The company had revenue of $10 million for the quarter, compared to the consensus estimate of $3.95 million. During the same quarter in the prior year, the company posted ($0.49) EPS. Epizyme’s quarterly revenue was up 2027.7% on a year-over-year basis. On average, equities research analysts forecast that Epizyme will post ($2.43) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/09/epizymes-epzm-buy-rating-reiterated-at-hc-wainwright.html.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $13.44, for a total transaction of $201,600.00. Following the sale, the insider now directly owns 22,228 shares of the company’s stock, valued at $298,744.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Robert A. Copeland sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $13.45, for a total value of $33,625.00. Following the sale, the insider now directly owns 34,038 shares in the company, valued at $457,811.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,524 shares of company stock worth $746,797. 25.20% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of EPZM. Palo Alto Investors LLC raised its stake in Epizyme by 57.8% in the first quarter. Palo Alto Investors LLC now owns 4,791,051 shares of the biopharmaceutical company’s stock valued at $82,167,000 after buying an additional 1,755,255 shares during the period. Vanguard Group Inc. raised its stake in Epizyme by 4.5% in the first quarter. Vanguard Group Inc. now owns 3,218,862 shares of the biopharmaceutical company’s stock valued at $55,202,000 after buying an additional 139,066 shares during the period. Foresite Capital Management II LLC raised its stake in Epizyme by 1.1% in the first quarter. Foresite Capital Management II LLC now owns 1,543,118 shares of the biopharmaceutical company’s stock valued at $26,464,000 after buying an additional 16,481 shares during the period. State Street Corp raised its stake in Epizyme by 1.6% in the first quarter. State Street Corp now owns 1,105,723 shares of the biopharmaceutical company’s stock valued at $18,960,000 after buying an additional 17,088 shares during the period. Finally, Foresite Capital Management III LLC raised its stake in Epizyme by 12.7% in the first quarter. Foresite Capital Management III LLC now owns 681,922 shares of the biopharmaceutical company’s stock valued at $11,695,000 after buying an additional 76,683 shares during the period. 81.30% of the stock is currently owned by hedge funds and other institutional investors.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.